Anti-Cancer Drug CAS 159351 -69-6 Everolimus Everolimus

China Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus, Find details about China Everolimus, Everolimus Supplier from Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Model NO.
159351-69-6
MOQ
1kg
COA
Available
MSDS
Available
Delivery
by Air, by Sea, by Courier
Lead Time
3 Days
Shelf Life
2 Years
Name
Tianeptine Sodium
CAS
30123-17-2
Alias
Tianeptine Sodium
Shipping
Worldwidce
Trademark
Monad
Transport Package
25kg/Drum
Specification
According to customer request
Origin
China
HS Code
2912491000
Model NO.
159351-69-6
MOQ
1kg
COA
Available
MSDS
Available
Delivery
by Air, by Sea, by Courier
Lead Time
3 Days
Shelf Life
2 Years
Name
Tianeptine Sodium
CAS
30123-17-2
Alias
Tianeptine Sodium
Shipping
Worldwidce
Trademark
Monad
Transport Package
25kg/Drum
Specification
According to customer request
Origin
China
HS Code
2912491000

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus
Anti-cancer Drug CAS 159351-69-6 Everolimus Everolimus
Product nameEverolimus
CAS No.159351-69-6  
EINECS No. 621-003-9
Purity99.90%
AppearanceWhite Crystal Powder
GradeMedical Grade
Expiration date2 Year
MOQ100G

Anti-cancer Drug CAS 159351-69-6 Everolimus Everolimus 
Name:Everolimus
Appearance:white powder
Synonyms:    Everolimus(mixture of isomers);Everolimus powder;CERTICAN; ZORTRESS; AFINITOR;Rapamycin, 42-O-(2-hydroxyethyl)-;Everolimus;Certican;CERTICAN(R);EveroliMus(RAD-001)
CAS:    159351-69-6
MF:    C53H83NO14
MW:    958.22
EINECS:    621-003-9

Everolimus, an orally adminstered rapamycin analog, has recently been approved by the FDA for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling. Everolimus significantly increased progression-free survival (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for the placebo group), although tumor regressions were observed only infrequently. While the target for everolimus, (the serine/threonine kinase mTOR) is well established, the mechanism by which this agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed. 
Everolimus is a medication used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.


Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced by growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.


Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus
Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus
Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus
Wuhan Monad Medicine Tech Co.,LTD is located in Hubei province of China.As one of the most dynamic foreign trade companies in the Chinese market, we own a registered capital of 1 million yuan. 
Besides, we have a pharmaceutical raw material production plant with high capacity production lines.
We also have a reagent R&D Center in which tens of thousands of reagents have been developed.
We also cover the business of custom synthesis of various organic compounds as a supplement.
we can synthesize almost all the chemicals

We have clients throughout the world,including Europe, South America, North America, Southeast Asia and Africa. 
Our business is based on honesty and mutual-trust.Sincerely looking forward to establish long term and mutual beneficial business relationship with worldwide customers."

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus
 Iron drum & plastic drum packaging

• 1000kg/drum

• 850kg/drum

• 200kg/drum&plastic drum

• 180kg/drum&plastic drum

• 25kg/plastic drum


Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

1.OEM/ODM Available.
2. Raw materials from chinese origin
3. Best quality in your requirement
4. Competitive price in china market
5 Fast delivery and free sample for your evaluation.Stock availability
6.Door to door shipping service is available.
7. Professional documents for your custom clearance.
8. Full experience of large numberscontainers loading in chinese sea port
9. Packing with pallet or as buyer's special request
10. Best after-service after shipment



Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus

Q1 what's the moq?
A: Usually our MOQ is 1kg.But it is based on the different product. Some are 10g.

Q2:Which kind of payment terms do you accept?
A: Payment by T/T, Western Union or Bitcoin.

Q3.Which transportation do we use?
A:Samples could be DHL, UPS, TNT, EMS, Fedex, and so on. For mass orders, it will be delivered by air or sea.

Q4:How about your delivery time?
Generally, it will take 3 to 5 days after receiving your advance payment.

Q5:How do you treat quality complaint?
A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss. 

Q6. How can we trust you?
A: You are always warm welcomed to visit us at any time.Before we start B2B, MIC has audited our company on-spot and approved our credit.

Q7.Do you test all your goods before delivery?
A:Yes, we have 100% test before delivery,International Authorized Third-Party Test for the products if you need are highly welcomed. 



Anti-Cancer Drug CAS 159351-69-6 Everolimus Everolimus